You seem to infer that the company's only pathway to success or additional funding is on the back of the pediatrics FDA outcome for Remestemcel-L / sr-GVHD ?
You clearly overlooked the fact that the CHF FDA meeting has finally taken place and Mesoblast will receive the minutes next month (March) - that will have an impact on funding / partnership for that indication so there are potential $ there ......
...... and then of course the 17th March due date for the 122 million shares / overhang from the CR in December will most likely be awarded to a CLBP partner so I am not as worried about $$ as you seem to be - I still anticipate if they receive enough money through the sale of these remaining shares (at a likely premium to 30 cents for a decent stake in the company) they will more than likely payout Oaktree but I guess we will see if and when these shares find a home ?
GLTAH
Ann: Half Year Report and Accounts (including Appendix 4D), page-9
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |